Loading...
•
Dec 31, 2024
biote Q4 2024 Earnings Report
Biote reported revenue growth with an improved gross margin, despite challenges in procedure volume.
Key Takeaways
Biote's Q4 2024 revenue reached $49.8 million, marking a 9.0% increase year-over-year. The company achieved a gross profit margin of 71.8% and reported a net income of $3.5 million. Adjusted EBITDA grew to $15.1 million, reflecting a strong 30.3% margin. However, procedure revenue growth was impacted by clinic software transitions and training focus.
Total revenue for Q4 2024 was $49.8 million, a 9.0% increase year-over-year.
Gross profit margin improved to 71.8%, up from 69.4% in Q4 2023.
Net income was $3.5 million, compared to $12.1 million in Q4 2023.
Adjusted EBITDA increased to $15.1 million, with a 30.3% margin.
Revenue by Segment
Forward Guidance
Biote expects moderate revenue growth in 2025, focusing on expanding its practitioner network and increasing supplement sales.
Positive Outlook
- Projected revenue of $202M-$208M for FY 2025.
- Procedure revenue expected to grow 2-4% in 2025.
- Dietary supplements revenue forecasted to grow 5-10% in 2025.
- Company aims to enhance practitioner training and onboarding.
- Continued efficiency improvements from vertical integration.
Challenges Ahead
- Clinic software transition impacted procedure volume in Q4 2024.
- Higher legal and employee-related expenses reduced operating income.
- Q1 2025 Adjusted EBITDA expected to decline by 5% due to higher marketing costs.
- Macroeconomic conditions may impact patient demand for elective procedures.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...